Table of Contents
1 INDUSTRY OUTLOOK 9
1.1 Industry overview 9
1.2 Industry Trends 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 12
3 Market Snapshot 14
3.1 Market Definition - Infoholic Research 14
3.2 Segmented Addressable Market (SAM) 14
3.3 Trends of the biosimilars market 14
3.4 Related Markets 16
3.4.1 Over the counter drugs 16
3.4.2 Orphan drugs 17
3.4.3 Human Insulin 18
4 Market Outlook 19
4.1 Biosimilar products approved in US 19
4.2 Biosimilar products approved in Europe 21
4.3 Biologics patent expiration in US and Europe (2010-2020) 27
4.4 Market segmentation 28
4.5 PEST Analysis 28
4.6 Porter 5(Five) Forces 29
5 Market Characteristics 31
5.1 DRO - Global Biosimilars Market Dynamics 31
5.1.1 Drivers 31
5.1.1.1 Increasing incidence of disease 31
5.1.1.2 Cost-effectiveness of biosimilars than biologics 32
5.1.1.3 Strategic collaboration to develop new biosimilar drugs 33
5.1.2 Opportunities 33
5.1.2.1 Promising pipeline of biosimilars 33
5.1.2.2 Opportunities in emerging market 34
5.1.3 Restraints 34
5.1.3.1 Limited obtainability of biosimilar products 34
5.1.3.2 Difficult manufacturing process and high development cost 35
6 Product: Market Size and Analysis 38
6.1 Overview 38
6.2 Recombinant glycosylated proteins 38
6.2.1 Monoclonal antibody 40
6.2.2 Erythropoietin 41
6.3 Recombinant non-glycosylated proteins 41
6.3.1 Recombinant human growth hormone 43
6.3.2 Granulocyte colony stimulating factor 43
6.3.3 Insulin 43
6.3.4 Interferon 44
6.4 Recombinant peptides and others 44
7 Application: Market Size and Analysis 45
7.1 Overview 45
7.2 Cancer 45
7.3 Blood disorders 46
7.4 Chronic and immune disease 47
7.5 Infectious disease 48
7.6 Others 49
8 Regions: Market Size and Analysis 50
8.1 Overview 50
8.2 North America 51
8.2.1 US 52
8.2.2 Canada 53
8.3 Europe 53
8.3.1 UK 54
8.3.2 Germany 55
8.3.3 France 55
8.3.4 Spain 55
8.4 Asia Pacific 56
8.4.1 India 57
8.4.2 China 57
8.4.3 Japan 58
8.5 Rest of the World 58
9 Competitive Landscape 60
9.1 Overview 60
10 Vendor Profiles 63
10.1 Pfizer' Inc.' 63
10.1.1 Overview 63
10.1.2 Business Units 66
10.1.3 Geographic Presence 67
10.1.4 Business Focus 67
10.1.5 SWOT Analysis 68
10.1.6 Business Strategies 68
10.2 Novartis AG 69
10.2.1 Overview 69
10.2.2 Business Units 72
10.2.3 Geographic Revenue 73
10.2.4 Business Focus 74
10.2.5 SWOT Analysis 74
10.2.6 Business Strategies 75
10.3 Celltrion Healthcare 76
10.3.1 Overview 76
10.3.2 Business Focus 79
10.3.3 SWOT Analysis 80
10.3.4 Business Strategy 80
10.4 Dr. Reddy's Laboratories Limited 81
10.4.1 Overview 81
10.4.2 Business Unit 86
10.4.3 Geographic Presence 86
10.4.4 Business Focus 87
10.4.5 SWOT Analysis 88
10.4.6 Business Strategy 88
10.5 Biocon Ltd 89
10.5.1 Overview 89
10.5.2 Business Unit 92
10.5.3 Geographic Presence 92
10.5.4 Business focus 93
10.5.5 SWOT analysis 93
10.5.6 Business Strategy 94
10.6 Teva Pharmaceutical Industries Ltd. 95
10.6.1 Overview 95
10.6.2 Business Unit 97
10.6.3 Geographic Presence 98
10.6.4 Business focus 99
10.6.5 SWOT analysis 99
10.6.6 Business Strategy 100
10.7 STADA Arzneimittel AG 100
10.7.1 Overview 100
10.7.2 Business Unit 102
10.7.3 Geographic Presence 103
10.7.4 Business focus 104
10.7.5 SWOT analysis 104
10.7.6 Business Strategy 105
11 Companies to Watch For 106
11.1 Amgen Inc. 106
11.1.1 Overview 106
11.2 Mylan N.V. 109
11.2.1 Overview 109
11.2.2 MYLAN N.V.: Recent Developments 110
11.3 Synthon Pharmaceuticals Inc.' 111
11.3.1 Overview 111
11.3.2 Synthon Pharmaceuticals Inc.: Recent Developments 111
11.4 Samsung Bioepis Co.' Ltd. 112
11.4.1 Overview 112
11.4.2 SAMSUNG BIOEPIS CO.' LTD: Recent Developments 113
12 Annexure 115
12.1 Abbreviations 115